Experts say more than 90% of drugs have room to cut prices

National People's Congress representative, Guangxi Huahong Pharmaceutical Stakes Chairman Wei Feiyan for the current state of the pharmaceutical market to express their views, said that "more than 90% of themedicinehave room to reduce prices, prices cut by 50%, no problem at all." "But it's worth noting that under the current system, it's still hard to get drug companies to cut prices."the price ofdrugs" for more than 10 years, the government has implemented drug price reduction more than 30 times, but 'the higher the drop'Wei Feiyan's words resonated with public opinionBut a number of people told reporters that pharmaceutical companies are also vulnerable to the pressure to reduce prices"China'sdrug pricesyears through bidding, secondary bargaining has been very lowMrShi said in an interview that the profit margins of pharmaceutical companies are not as good as they used to beIf prices are pushed again, some pharmaceutical companies may have to give up production, Shi Lichen, for example, the profit margin of the production of generic drugs enterprises is about 5% to 8%, the profit margin of circulation enterprises is about 2%, and then the end product sales generated by the drug plus, the total profit margin is not more than 25%, and these generic drugs account for half of the drug marketThere is a high profit margin of a class of products - the exclusive OTC products sold by pharmacies, the profit margin of pharmaceutical companies is up to more than 20%, the profit margin of circulation enterprises is about 6%-10%, and the profit margin to the sales terminal is 10%-20%But some products sold in the hospital product price is uncertain, such as the ex-factory price of 15 yuan of drugs, the hospital may sell to 45 yuan but a pharmaceutical industry observer told reporters that in the future under the pressure of health insurance charges, drug tenders will continue to reduce prices as the main trend 2015 is a big year of pharmaceutical bidding, enterprises in the drug tender price decline trend, how to play games with the government, maintain development, but also the focus of the market in January this year, more than 200 pharmaceutical companies jointly signed a book, that Hunan drug centralized procurement bargaining is too low Some drug companies argue that the government's offer is far below what companies can afford , a listed pharmaceutical company head in an interview with this newspaper, said that if the price reduction in Hunan than other regions, then other regions will follow suit, which will affect the company's drug price system "But if you don't accept the tender, it means losing the market and it's hard for companies to choose." "
system dysentery pharmaceutical companies do not want to go down, but dare not to drop Hospital rebates are one of them In order to lower the price of medicine, "drug-based medicine" is an unavoidable topic, and the real reason behind it is the "tangle" brought about by the institutional problems the lack of financial investment of the government is an important reason for the existence of the phenomenon of "drug-based medicine" According to media reports, China's total health costs as a proportion of GDP has been maintained at about 5%, while the global average of about 9.7%, the United States health costs as a proportion of GDP reached 16% Inadequate financial support has led to hospitals having to be 'self-reliant', and selling medicines is one of the sources of hospital revenue it is understood that the current medical insurance directory of the drug prices form the formation of multi-sector coordination: the National Development and Reform Commission and provincial price departments to establish the highest retail price, provincial tender departments to form the actual supply price, enterprise drugs into the hospital cost plus sales, medical insurance in accordance with the drug health insurance level to be reimbursed There are secondary bargaining conditions in some areas under such a system, drug price cuts will also form a "strange phase": after drug price adjustment, hospitals may give up the use of reduced-price drugs, manufacturers and then give up the production of reduced-price drugs, instead of various changes in the specifications of "new drugs." A person familiar with the matter told reporters that many of the so-called new drugs are just "old bottles of wine", but the price is high